ELEVATE IPF is a phase 2b randomized, double-blind dose exploration trial aimed at IPF patients, evaluating the efficacy and safety of two doses of deupirfenidone three times a day (TID) compared to the approved drug pirfenidone (801 mg) and placebo after 26 weeks of use.
Analysis shows that the experiment successfully achieved the primary endpoint. At week 26 of the experiment, taking 825 mg of deepirfenidone three times a day significantly reduced the decrease in forced vital capacity (FVC) in patients, showing a statistically significant difference compared to placebo (-21.5 mL vs. -112.5 mL, p=0.02), indicating a significant therapeutic effect of 80.9%. In addition, the trial also demonstrated significant dose-dependent efficacy. Generally speaking, the natural decrease in FVC within 6 months for healthy individuals aged 60 and above is approximately -15.0 mL to -25.0 mL. The therapeutic effect of the active control drug three times a day compared to placebo was 54.1% (-51.6 mL vs. -112.5 mL), consistent with previous clinical trial results of the drug.
The trial also achieved key secondary endpoints, indicating that deepirfenidone treatment was superior to the placebo group in slowing down the decline of FVC percentage prediction value (FVCpp). FVCpp is another measure of lung function that takes into account key characteristics such as age, gender, height, and race of patients, in addition to FVC itself, in order to standardize at the patient level. Deupirfenidone also showed statistically significant differences at this endpoint (-0.43 vs. -3.43, p=0.01), further confirming its therapeutic effect.
In addition, the experimental results showed that both doses of deepirfenidone were well tolerated and had safety characteristics consistent with previous studies.
Deupirfenidone is deuterated pirfenidone, which is one of the two standard therapies used alongside nintedanib for the treatment of IPF. Through deuterium modification, deepirfenidone has a slower metabolic rate in vivo, which may prolong the drug's duration of action and improve its efficacy.
<Reprinted from WuXi AppTec>







